Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China · Delayed Price · Currency is CNY 14.79
+0.05 (0.34%)
Feb 3, 2026, 11:25 AM CST
SHA:600535 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 8,316 | 8,468 | 8,636 | 8,606 | 7,898 | 13,505 |
Other Revenue | 29.81 | 29.81 | 37.71 | 31.19 | 53.86 | 70.82 |
| 8,346 | 8,498 | 8,674 | 8,637 | 7,952 | 13,576 | |
Revenue Growth (YoY) | -2.56% | -2.03% | 0.42% | 8.62% | -41.43% | -28.54% |
Cost of Revenue | 2,747 | 2,810 | 2,885 | 3,147 | 2,682 | 8,115 |
Gross Profit | 5,599 | 5,688 | 5,789 | 5,490 | 5,269 | 5,461 |
Selling, General & Admin | 3,400 | 3,334 | 3,326 | 3,267 | 3,339 | 3,215 |
Research & Development | 818.73 | 830.07 | 917.27 | 845.34 | 579.53 | 689.33 |
Other Operating Expenses | 92.98 | 87.98 | 96.46 | 37.96 | 110.64 | 104.05 |
Operating Expenses | 4,326 | 4,252 | 4,348 | 4,149 | 4,027 | 4,073 |
Operating Income | 1,273 | 1,436 | 1,441 | 1,341 | 1,243 | 1,388 |
Interest Expense | -28.12 | -61.28 | -82.52 | -64.86 | -77.39 | -286.69 |
Interest & Investment Income | 61.95 | 91.05 | 107.55 | 107.55 | 1,792 | 241.04 |
Currency Exchange Gain (Loss) | -1.07 | -1.07 | -1.23 | -1.61 | 7.27 | 5.58 |
Other Non Operating Income (Expenses) | -7.92 | -3.52 | -4.73 | -71.11 | 0 | -11.05 |
EBT Excluding Unusual Items | 1,298 | 1,461 | 1,460 | 1,311 | 2,965 | 1,337 |
Impairment of Goodwill | -15.88 | -15.88 | - | -151.2 | - | -59.01 |
Gain (Loss) on Sale of Investments | 59.71 | -213.45 | -282.81 | -1,125 | -79.88 | 118.21 |
Gain (Loss) on Sale of Assets | 9.19 | 2.11 | 0.15 | -4.93 | 41.27 | -5.67 |
Asset Writedown | -162.96 | -202.13 | -1.78 | -194.64 | -262.53 | - |
Other Unusual Items | 36.78 | 36.78 | 45.51 | -1.96 | 60.04 | 66.91 |
Pretax Income | 1,225 | 1,069 | 1,221 | -167.63 | 2,724 | 1,457 |
Income Tax Expense | 201.42 | 209.63 | 204.46 | 180.82 | 315.92 | 367.2 |
Earnings From Continuing Operations | 1,023 | 859.06 | 1,017 | -348.46 | 2,408 | 1,090 |
Minority Interest in Earnings | 74.3 | 96.53 | 54.43 | 84.22 | -48.75 | 36.03 |
Net Income | 1,098 | 955.59 | 1,071 | -264.24 | 2,359 | 1,126 |
Net Income to Common | 1,098 | 955.59 | 1,071 | -264.24 | 2,359 | 1,126 |
Net Income Growth | 24.60% | -10.78% | - | - | 109.51% | 12.43% |
Shares Outstanding (Basic) | 1,485 | 1,494 | 1,488 | 1,468 | 1,502 | 1,501 |
Shares Outstanding (Diluted) | 1,485 | 1,494 | 1,488 | 1,468 | 1,502 | 1,501 |
Shares Change (YoY) | -0.60% | 0.43% | 1.34% | -2.29% | 0.08% | -1.06% |
EPS (Basic) | 0.74 | 0.64 | 0.72 | -0.18 | 1.57 | 0.75 |
EPS (Diluted) | 0.74 | 0.64 | 0.72 | -0.18 | 1.57 | 0.75 |
EPS Growth | 25.35% | -11.16% | - | - | 109.33% | 13.64% |
Free Cash Flow | 1,236 | 1,450 | 1,907 | 1,875 | 2,229 | 1,382 |
Free Cash Flow Per Share | 0.83 | 0.97 | 1.28 | 1.28 | 1.48 | 0.92 |
Dividend Per Share | 0.200 | 0.530 | 0.330 | 0.330 | 0.330 | 0.330 |
Dividend Growth | -69.70% | 60.61% | - | - | - | - |
Gross Margin | 67.08% | 66.94% | 66.74% | 63.56% | 66.27% | 40.23% |
Operating Margin | 15.25% | 16.90% | 16.61% | 15.52% | 15.63% | 10.22% |
Profit Margin | 13.15% | 11.24% | 12.35% | -3.06% | 29.66% | 8.29% |
Free Cash Flow Margin | 14.81% | 17.06% | 21.98% | 21.71% | 28.04% | 10.18% |
EBITDA | 1,588 | 1,832 | 1,946 | 1,774 | 1,648 | 1,927 |
EBITDA Margin | 19.03% | 21.56% | 22.43% | 20.54% | 20.72% | 14.20% |
D&A For EBITDA | 314.91 | 396.34 | 504.91 | 433.92 | 405.08 | 539.67 |
EBIT | 1,273 | 1,436 | 1,441 | 1,341 | 1,243 | 1,388 |
EBIT Margin | 15.25% | 16.90% | 16.61% | 15.52% | 15.63% | 10.22% |
Effective Tax Rate | 16.44% | 19.62% | 16.74% | - | 11.60% | 25.20% |
Revenue as Reported | 8,346 | 8,498 | 8,674 | 8,637 | - | 13,576 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.